[A trial of immunological correction in patients with frequently recurring chronic inflammatory gynecological diseases]

Akusherstvo i ginekologiia · 1991 · vol. 30(2) , pp. 30–3 · PMID:1883043 · W2429312044
Non-randomised trial OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-28 ⓘ

This trial evaluated immunomodulators, particularly levamisole, in 67 patients with frequently relapsing inflammatory gynecological diseases, finding that adding these agents to complex therapy induced a significant antirelapsing effect.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Various immunomodulating drugs: levamizol in suppression of CMI and phagocytosis, gamma A in deficit of antibody synthesis and vitamins A, E, C, in patients with suppression of all immunological parameters, were added to the complex treatment of 67 patients with frequently relapsing inflammatory gynecological diseases and data for suppression of various components of the immune response. Inclusion of immunomodulators to the complex therapy induces a definite antirelapsing effect. Levamizol was of the highest clinical efficiency, presenting a definite antirelapsing effect of 66.67% of the patients, treated and observed for a period of a year.

My notes (saved in your browser only)

MeSH descriptors

Adjuvants, Immunologic Genital Diseases, Female Adjuvants, Immunologic Adult Antioxidants Antioxidants Chronic Disease Combined Modality Therapy Drug Evaluation Female Genital Diseases, Female Humans Immunization, Passive Inflammation Inflammation Levamisole Levamisole Recurrence

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:43.569505+00:00
License: CC0 · commercial use OK